Albumin Market Size & Share, by Type (Recombinant, Human Serum, Bovine), Grade (Food Grade, Diagnostic Grade, Reagent Grade), Application (Drug Formulation & Vaccines, Therapeutics, Research) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 5035
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Albumin Market size was over USD 5.68 billion in 2024 and is poised to reach USD 12.51 billion by the end of 2037, growing at around 6.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of albumin is assessed at USD 5.97 billion.

The rising cases of liver diseases and infection have increased the demand for albumin, thus, driving market growth. The worldwide incidence of cirrhosis from autopsy results ranges from 4.5% to 9.5% of the population as a whole. It is estimated that in the next few years, more than fifty million adults worldwide will be afflicted with chronic liver disease. In the liver diseases, such as Ascites, albumin is used as a component for removing excess fluid from the abdomen. It helps prevent complications such as renal dysfunction and hypovolemia by maintaining plasma volume.

Furthermore, the rising discovery of new albumins is expected to augment the market growth. In April 2022, the article Impact of Serum Albumin Levels on COVID-19 Mortality implied that during admission if a COVID patient is injected with low levels of albumin serum. It can identify the patient who is at high risk of pneumonia and respiratory failure.


Get more information on this report: Request Free Sample PDF

Albumin Market: Growth Drivers and Challenges

Growth Drivers

  • Growing Number of Cardiac Surgeries– In the world, to treat various cardiac conditions around 2 million people undergo open-heart surgeries, every year. During cardiac surgery, patients may experience significant blood loss, requiring the replacement of fluids and blood products. Albumin is an ideal plasma expander as it helps restore blood volume and maintain hemodynamic stability.
  • Increasing Use of Albumin in Cell Culture R&D Activities– Albumin is commonly included in cell culture media to provide essential nutrients, growth factors, and a stable environment for cell growth and maintenance. Moreover, it is also applied in the development of drug delivery systems, it employs albumin as a carrier or stabilizer. Its ability to bind and transport various substances makes it an excellent candidate for delivering drugs.
  • Growing Development of Plant-Based Albumins– The demand for plant-based albumins is rising owing to the desire to reduce reliance on animal-derived products. Moreover, plant-based albumins offer the opportunity for customization and functional modification. The customization, includes, optimizing solubility, stability, and binding capabilities, which can be beneficial in various industrial processes and formulation. Moreover, researchers are developing new plant-based albumins by genetic engineering or optimizing plant sources.

Challenges

  • Negative Reaction of Albumins – Although uncommon, some individuals may develop allergic reactions to albumin. These reactions can range from mild symptoms like skin, rash, itching, or hives to more severe effects, such as chest tightness, difficulty in breathing, or anaphylaxis. Allergic reactions are more likely in individuals with known allergies to albumin or other proteins. Moreover, Albumins have the potential to bind with certain drugs, affecting their distribution and efficacy.
  • Tough Competition from other Substitutes
  • Stringent Regulation Policies & Lack of Adequate Reimbursement

Albumin Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

6.4%

Base Year Market Size (2024)

USD 5.68 billion

Forecast Year Market Size (2037)

USD 12.51 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Albumin Segmentation

Type (Recombinant Albumin, Human Serum Albumin, Bovine Albumin)

The human serum albumin segment is estimated to hold over 55% share of the albumin market in the year 2037. The segment growth is due to a rise in the number of new drug development followed by higher expenditure in the R&D in the pharmaceutical industry. Within the next five years, through 2026, more than three hundred new medications are scheduled to be introduced onto the market. This is a considerable rise above the preceding decade’s average. Moreover, globally around USD 196 billion is expected to be invested in the research of new drugs. Human serum albumin is often used in the formulation of drugs to improve their stability, solubility, and bioavailability. Human serum albumin increases drug solubility, especially for poorly water-soluble compounds. Moreover, it also acts as a stabilizer, preventing degradation or aggregation of drug molecules.

Application (Drug Formulation & Vaccines, Therapeutics, Research)

The therapeutics segment is expected to accumulate a notable revenue share of around 45% in the year 2037. Rising cases of severe burns and other traumas will drive the growth of the segment. Severe burns lead to extensive fluid loss and dehydration. Albumin is used as a plasma expander to restore and maintain intravascular volumes, and it is also used for maintaining oncotic pressure restoration.

Our in-depth analysis of the global market includes the following segments:

         Type

  • Recombinant Albumin
  • Human Serum Albumin
  • Bovine Albumin

        Grade

  • Food Grade
  • Diagnostic Grade
  • Reagent Grade

        Application

  • Drug Formulation & Vaccines
  • Therapeutics
  • Research
 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Albumin Industry - Regional Synopsis

North American Market Forecast

The albumin market in North America is projected to be the largest with a share of about 35% by the end of 2037. The growth of the market can be attributed majorly to the increasing production of immunoglobins and this is further driven by a rise in the number of HIV patients. Moreover, in 2021, Pfizer Inc. received the approval of the U.S. Food and Drug Administration (FDA) for the application of (sBLA) for PANZYGA, it is an intravenous immunoglobulin for treating the patient suffering from chronic inflammatory demyelinating polyneuropathy (CIDP).

APAC Market Forecast

The Asia Pacific albumin market is estimated to be the second largest, registering a share of about 28% by the end of 2037. The higher number of people suffering from heart issues will boost the market growth in the region. Albumin’s ability to exert oncotic pressure, which is important during cardiac surgery to prevent edema and ensure proper perfusion. Over the last several decades, projections of the overall incidence of coronary heart disease in India have dramatically increased from around 1.6% to nearly 7.4% in rural populations and from 1% to 13.2% in urban populations.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Albumin Landscape

    • Apotex Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Octapharma AG
    • Bio Med International Pvt. Ltd.
    • Baxter
    • Novozymes
    • Mitsubishi Tanabe Pharma America Inc.
    • Merck KGaA
    • Akron Biotech
    • Thermo Fisher Scientific
    • Grifols, S.A.

In the News

  •  Apotex Corp. announced the launch of Paclitaxel, a generic version of Abrazane, it is a protein-bind particle for injection. These injections have especially been curated for the treatment of people suffering from non-small cell lung cancer, metastatic breast cancer, and adenocarcinoma of the pancreas.
  • Grifols, S.A. announced the launch of Albutein FlexBag in the concentration of 5% and 25%. It is available in ecologically sustainable packaging, which gives healthcare professionals a more environmentally friendly solution.

Author Credits:  Radhika Pawar


  • Report ID: 5035
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of albumin is assessed at USD 5.97 billion.

The albumin market size was over USD 5.68 billion in 2024 and is poised to reach USD 12.51 billion by the end of 2037, growing at around 6.4% CAGR during the forecast period i.e., between 2025-2037. Rising demand for immunoglobulins, higher production of new drugs, and rising cases of liver diseases and coronary issues will boost the market growth.

North America industry is predicted to be the largest with a share of about 35% by 2037, owing to increasing production of immunoglobins along with rise in the number of HIV patients in the region.

The major players in the market include Apotex Inc., Octapharma AG, Bio Med International Pvt. Ltd., Baxter, Novozymes, Mitsubishi Tanabe Pharma America Inc., Merck KGaA, Akron Biotech, Thermo Fisher Scientific, Grifols, S.A.
Albumin Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample